$NMRD
Nemaura Medical Inc. Stock $nmrd

$nmrd Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000107997323000949 Filed on July 13, 2023

Income Statement

Concept	2023 Q3	2023 Q1	2023
Revenue	$0.00	$0.00	$77.04K
YoY Change	-100.0%	-100.0%	-84.71%
Cost Of Revenue	$0.00	$0.00	$75.33K
YoY Change	-100.0%	-100.0%	-78.12%
Gross Profit	$0.00	$0.00	$1.710K
YoY Change	-100.0%	-100.0%	-98.93%
Gross Profit Margin			2.22%
Selling, General & Admin	$1.560M	$1.271M	$5.600M
YoY Change	-32.76%	-37.14%	-9.28%
% of Gross Profit			327496.49%
Research & Development	$491.8K	$557.8K	$1.539M
YoY Change	91.32%	-2.03%	-1.18%
% of Gross Profit			89977.78%
Depreciation & Amortization	$130.0K	$175.6K	$444.2K
YoY Change	75.94%	94.96%	93.28%
% of Gross Profit			25975.44%
Operating Expenses	$2.051M	$1.829M	$7.139M
YoY Change	-20.43%	-29.42%	-7.65%
Operating Profit	-$2.051M	-$1.829M	-$7.137M
YoY Change	-20.38%	-25.14%	-5.72%
Interest Expense	-$860.0K	-$396.1K	-$4.549M
YoY Change	-42.79%	-74.03%	-31.77%
% of Operating Profit
Other Income/Expense, Net	$1.710M	$1.864M	$1.864M
YoY Change
Pretax Income	-$1.200M	-$4.683M	-$14.14M
YoY Change	-70.58%	18.03%	-0.66%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.203M	-$4.683M	-$14.14M
YoY Change	-70.49%	29.46%	1.85%
Net Earnings / Revenue			-18358.96%
Basic Earnings Per Share	-$0.05		-$0.57
Diluted Earnings Per Share	-$0.05	-$0.17	-$0.57
COMMON SHARES
Basic Shares Outstanding	28.90M shares	28.90M shares	24.88M shares
Diluted Shares Outstanding	28.90M shares		24.88M shares

Balance Sheet

Concept	2023 Q3	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.380M	$10.11M	$10.11M
YoY Change	-86.35%	-43.07%	-43.07%
Cash & Equivalents	$1.378M	$10.11M
Short-Term Investments
Other Short-Term Assets	$3.490M	$1.268M	$1.268M
YoY Change	80.44%	68.98%	167.54%
Inventory	$2.911M	$1.755M	$1.755M
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$409.7K	$409.7K
Total Short-Term Assets	$8.062M	$13.54M	$13.54M
YoY Change	-42.22%	-32.61%	-32.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$582.5K	$641.9K	$641.9K
YoY Change	11.63%	20.54%	20.54%
Goodwill
YoY Change
Intangibles		$384.1K
YoY Change		-74.07%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$856.2K	$1.026M	$1.026M
YoY Change	-56.07%	-49.04%	-49.04%
TOTAL ASSETS
Total Short-Term Assets	$8.062M	$13.54M	$13.54M
Total Long-Term Assets	$856.2K	$1.026M	$1.026M
Total Assets	$8.919M	$14.56M	$14.56M
YoY Change	-43.92%	-34.11%	-34.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$418.8K	$326.6K	$326.6K
YoY Change	39.09%	139.63%	139.63%
Accrued Expenses	$190.0K	$130.7K	$130.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.55M	$16.94M	$16.94M
YoY Change	0.88%	-11.71%	-11.71%
Total Short-Term Liabilities	$21.43M	$22.27M	$22.27M
YoY Change	4.69%	8.19%	8.19%
LONG-TERM LIABILITIES
Long-Term Debt	$3.360M	$3.088M	$3.088M
YoY Change	-3.73%
Other Long-Term Liabilities	$0.00	$1.022M	$1.022M
YoY Change	-100.0%	-2.96%	-2.96%
Total Long-Term Liabilities	$3.360M	$4.109M	$4.109M
YoY Change	-24.43%	290.28%	290.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.43M	$22.27M	$22.27M
Total Long-Term Liabilities	$3.360M	$4.109M	$4.109M
Total Liabilities	$24.79M	$26.38M	$26.38M
YoY Change	-0.51%	21.92%	21.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.68M	-$51.88M
YoY Change	21.6%	37.49%
Common Stock	$41.02M	$41.02M
YoY Change	7.05%	7.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$15.87M	-$11.81M	-$11.81M
YoY Change
Total Liabilities & Shareholders Equity	$8.919M	$14.56M	$14.56M
YoY Change	-43.92%	-34.11%	-34.11%

Cashflow Statement

Concept	2023 Q3	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$1.203M	-$4.683M	-$14.14M
YoY Change	-70.49%	29.46%	1.85%
Depreciation, Depletion And Amortization	$130.0K	$175.6K	$444.2K
YoY Change	75.94%	94.96%	93.28%
Cash From Operating Activities	-$3.200M	-$2.362M	-$8.452M
YoY Change	47.81%	9.81%	29.95%
INVESTING ACTIVITIES
Capital Expenditures	$40.00K	$100.4K	$539.2K
YoY Change	-124.47%	-231.31%	-156.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$40.00K	-$100.4K	-$539.2K
YoY Change	-75.53%	31.31%	-43.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$8.394M
YoY Change			38.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.920M	5.356M	2.082M
YoY Change	-361.33%	-281.78%	-132.69%
NET CHANGE
Cash From Operating Activities	-3.200M	-2.362M	-8.452M
Cash From Investing Activities	-40.00K	-100.4K	-539.2K
Cash From Financing Activities	3.920M	5.356M	2.082M
Net Change In Cash	680.0K	2.894M	-6.909M
YoY Change	-117.76%	-155.94%	-50.04%
FREE CASH FLOW
Cash From Operating Activities	-$3.200M	-$2.362M	-$8.452M
Capital Expenditures	$40.00K	$100.4K	$539.2K
Free Cash Flow	-$3.240M	-$2.462M	-$8.991M
YoY Change	61.88%	18.7%	62.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001602078
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38355
CY2023	dei	Entity Registrant Name EntityRegistrantName	NEMAURA MEDICAL INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5027260
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
CY2023	dei	City Area Code CityAreaCode	646
CY2023	dei	Local Phone Number LocalPhoneNumber	416-8000
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Trading Symbol TradingSymbol	NMRD
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	25200000	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28899402	shares
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2023	dei	Auditor Name AuditorName	Weinberg & Company, P.A.
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C
CY2022	dei	Auditor Location AuditorLocation	Colorado
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10105135	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17749233	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	1487771	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	357934	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	495055	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	409648	usd
CY2022Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	255112	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	909666	usd
CY2022Q1	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	0	usd
CY2023Q1	nmrd	Receivable From Related Parties ReceivableFromRelatedParties	0	usd
CY2022Q1	nmrd	Receivable From Related Parties ReceivableFromRelatedParties	101297	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13537235	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	20088468	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641906	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	532508	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	384092	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1480980	usd
CY2023Q1	us-gaap	Assets Assets	14563233	usd
CY2022Q1	us-gaap	Assets Assets	22101956	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	326641	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	136310	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	130678	usd
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	558426	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	16942500	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	19188724	usd
CY2023Q1	nmrd	Payable To Related Parties PayableToRelatedParties	920780	usd
CY2022Q1	nmrd	Payable To Related Parties PayableToRelatedParties	0	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	123640	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	259256	usd
CY2023Q1	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	731730	usd
CY2022Q1	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	440196	usd
CY2023Q1	nmrd	Warrant Liability WarrantLiability	3092000	usd
CY2022Q1	nmrd	Warrant Liability WarrantLiability	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22267969	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20582912	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3087651	usd
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1021811	usd
CY2022Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1052960	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26377431	usd
CY2022Q1	us-gaap	Liabilities Liabilities	21635872	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24102866	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24102866	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	24103	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38295775	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51875211	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37731476	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-959263	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-122318	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14563233	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22101956	usd
CY2023	us-gaap	Revenues Revenues	77044	usd
CY2022	us-gaap	Revenues Revenues	503906	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	75328	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	344300	usd
CY2023	nmrd	Cost Of Salesinventory Write Down CostOfSalesinventoryWriteDown	1478108	usd
CY2022	nmrd	Cost Of Salesinventory Write Down CostOfSalesinventoryWriteDown	-0	usd
CY2023	us-gaap	Gross Profit GrossProfit	-1476392	usd
CY2022	us-gaap	Gross Profit GrossProfit	159606	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1538615	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1556988	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5600188	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6173049	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	980039	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	8118842	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	7730037	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-9595234	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-7570431	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6412501	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6666630	usd
CY2023	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1864000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14143735	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14237061	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-350256	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14143735	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13886805	usd
CY2023	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-836946	usd
CY2022	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-257885	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14980681	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14144690	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24878196	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24878196	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23383758	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23383758	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8358172	usd
CY2022	nmrd	Issuance Of Common Shares Net Of Costs IssuanceOfCommonSharesNetOfCosts	50765	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3068027	usd
CY2022	nmrd	Exercise Of Warrants Amount ExerciseOfWarrantsAmount	2963658	usd
CY2022	nmrd	Restricted Shares Issued As Stockbased Compensation Amount RestrictedSharesIssuedAsStockbasedCompensationAmount	87388	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	133529	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-257885	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13886805	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7656398	usd
CY2023	nmrd	Fair Value Of Warrant Liability Recognized In Connection With Issuance Of Common Shares Amount FairValueOfWarrantLiabilityRecognizedInConnectionWithIssuanceOfCommonSharesAmount	-4956000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-836946	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14143735	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-14143735	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-13886805	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	444177	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	229810	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1871593	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6666630	usd
CY2023	nmrd	Monitoring Fee Interest Expense Added To Notes Payable MonitoringFeeInterestExpenseAddedToNotesPayable	2240339	usd
CY2022	nmrd	Monitoring Fee Interest Expense Added To Notes Payable MonitoringFeeInterestExpenseAddedToNotesPayable	0	usd
CY2023	nmrd	Fees For Note Amendments Expense Added To Note Payable FeesForNoteAmendmentsExpenseAddedToNotePayable	2304539	usd
CY2022	nmrd	Fees For Note Amendments Expense Added To Note Payable FeesForNoteAmendmentsExpenseAddedToNotePayable	0	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1478108	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	980039	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023	nmrd	Change In Fair Value Of Foreign Exchange Contract ChangeInFairValueOfForeignExchangeContract	291534	usd
CY2022	nmrd	Change In Fair Value Of Foreign Exchange Contract ChangeInFairValueOfForeignExchangeContract	440196	usd
CY2023	nmrd	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	1864000	usd
CY2022	nmrd	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	-0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	220917	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1745189	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	637149	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17415	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-519346	usd
CY2023	nmrd	Deposit On Foreign Exchange Contracts DepositOnForeignExchangeContracts	909666	usd
CY2022	nmrd	Deposit On Foreign Exchange Contracts DepositOnForeignExchangeContracts	-0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	190331	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-117384	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-427748	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	310490	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-1022077	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	250092	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-166765	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8451781	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6504041	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	376170	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	481718	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	135168	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	83691	usd
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	27879	usd
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	391073	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-539217	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-956482	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8394056	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3118792	usd
CY2023	nmrd	Costs Incurred In Relation To Equity Financing CostsIncurredInRelationToEquityFinancing	737658	usd
CY2022	nmrd	Costs Incurred In Relation To Equity Financing CostsIncurredInRelationToEquityFinancing	50765	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2963658	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4700000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10274281	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12400000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2082117	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6368315	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6908881	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13828838	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-735217	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-287300	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31865371	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10105135	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2023	us-gaap	Interest Paid InterestPaid	0	usd
CY2022	us-gaap	Interest Paid InterestPaid	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	nmrd	Fair Value Of Warrant Liability Recognized In Connection With Issuance Of Common Shares FairValueOfWarrantLiabilityRecognizedInConnectionWithIssuanceOfCommonShares	4956000	usd
CY2022	nmrd	Fair Value Of Warrant Liability Recognized In Connection With Issuance Of Common Shares FairValueOfWarrantLiabilityRecognizedInConnectionWithIssuanceOfCommonShares	0	usd
CY2023	nmrd	Monitoring Fees Added To Notes Payable MonitoringFeesAddedToNotesPayable	2240339	usd
CY2022	nmrd	Monitoring Fees Added To Notes Payable MonitoringFeesAddedToNotesPayable	2764775	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14143735	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8451781	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zbW3CxOPUqYk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i><span id="xdx_864_zLE2O2MNsyd8">Use of estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation allowances. Actual results may differ from those estimates.<b> </b></p>
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	655641	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10105135	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17749233	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6409304	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1613098	shares
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	37645	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	24300	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zXFZ4QEzn7X1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i><span id="xdx_869_zpnvBYVheGKj">Reclassifications</span></i></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certain prior year balances have been reclassified to conform with the current year presentation. In presenting the Company’s consolidated balance sheet at March 31, 2022, the Company presented $<span id="xdx_90B_eus-gaap--ValueAddedTaxReceivable_iI_c20220331_zWZYIUf6iHrd" title="VAT receivable">255,112</span> VAT receivable as part of prepaid expenses and other receivables of $<span id="xdx_909_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20220331_zjLgSDpXNNfi" title="Prepaid expenses and other receivables">750,167</span>. In presenting the Company’s consolidated balance sheet at March 31, 2023, the Company has reclassified the balance of $<span id="xdx_908_eus-gaap--ValueAddedTaxReceivable_iI_c20230331_zxn5lED0jOb6" title="VAT receivable">255,112</span> as a separate line item VAT receivable, and the balance of $<span id="xdx_90E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20220331_zW1uqmMme1b1" title="Prepaid expenses balance">495,055</span> is presented as prepaid expenses in the accompanying March 31, 2022 financial statements.<i> </i></p>
CY2022Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	255112	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	750167	usd
CY2023Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	255112	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	495055	usd
CY2023Q1	us-gaap	Advance Royalties Current AdvanceRoyaltiesCurrent	1000000	gbp
CY2023Q1	us-gaap	Advance Royalties AdvanceRoyalties	1230000	usd
CY2022Q1	us-gaap	Advance Royalties AdvanceRoyalties	1320000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	1081676	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1586777	usd
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1481946	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	168075	usd
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5825	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	1487771	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1478108	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	998635	usd
CY2022Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	727250	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	114863	usd
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	78867	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1113498	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	806117	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	471592	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	273609	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641906	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	532508	usd
CY2023	us-gaap	Depreciation Depreciation	156000	usd
CY2022	us-gaap	Depreciation Depreciation	138000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	384092	usd
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1480980	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	193000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	324397	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	655641	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q1	nmrd	Warrants Issued WarrantsIssued	4796206	shares
CY2023Q1	nmrd	Volatility Interest Rate VolatilityInterestRate	1	pure
CY2022Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	6250000	usd
CY2022Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	12500000	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	250000	usd
CY2023	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	On each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the settlement date, the Company is obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty.
CY2023Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts Expired FairValueOfContractLiabilityLeveragedAmountsExpired	4000000	usd
CY2023	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2000000	usd
CY2023Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	4250000	usd
CY2022Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	6250000	usd
CY2023Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	8500000	usd
CY2022Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	12500000	usd
CY2023	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P17M
CY2022	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P25M
CY2023Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	731730	usd
CY2022Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	440196	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	909666	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20797234	usd
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20512400	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	767083	usd
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1323676	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	20030151	usd
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	19188724	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	16942500	usd
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	19188724	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3087651	usd
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
CY2021Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	148795	usd
CY2023	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	4767586	usd
CY2022	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	3245985	usd
CY2023	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	0	usd
CY2022	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	2495	usd
CY2023	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	3773217	usd
CY2022	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	3492962	usd
CY2023	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	27708	usd
CY2022	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	620	usd
CY2023Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	920780	usd
CY2022Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13314440	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-11716916	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-829295	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2520145	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-14143735	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-14237061	usd
CY2023	nmrd	Loss Before Income Taxes LossBeforeIncomeTaxes	-14143735	usd
CY2022	nmrd	Loss Before Income Taxes LossBeforeIncomeTaxes	-14237061	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3145943	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.22	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2989783	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	235938	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.02	pure
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	234338	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.02	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	369946	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.03	pure
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	463591	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.03	pure
CY2023	nmrd	Prior Year Trueup Of Nols PriorYearTrueupOfNols	-46393	usd
CY2023	nmrd	Income Tax Reconciliation Prior Year Trueup Of Nols IncomeTaxReconciliationPriorYearTrueupOfNols	0	pure
CY2022	nmrd	Prior Year Trueup Of Nols PriorYearTrueupOfNols	2401930	usd
CY2022	nmrd	Income Tax Reconciliation Prior Year Trueup Of Nols IncomeTaxReconciliationPriorYearTrueupOfNols	0.17	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	338278	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.02	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	74579	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2988066	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	742527	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.05	pure
CY2023	nmrd	Rd Credit Received RdCreditReceived	0	usd
CY2023	nmrd	Income Tax Reconciliation Rd Credit Received IncomeTaxReconciliationRdCreditReceived	0	pure
CY2022	nmrd	Rd Credit Received RdCreditReceived	350256	usd
CY2022	nmrd	Income Tax Reconciliation Rd Credit Received IncomeTaxReconciliationRdCreditReceived	0.02	pure
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	350256	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.02	pure
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9259000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6671000	usd
CY2023Q1	nmrd	Research And Development Enhancement ResearchAndDevelopmentEnhancement	361000	usd
CY2022Q1	nmrd	Research And Development Enhancement ResearchAndDevelopmentEnhancement	335000	usd
CY2023Q1	nmrd	Other Items OtherItems	38000	usd
CY2022Q1	nmrd	Other Items OtherItems	-335000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9658000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6671000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	0	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	350256	usd
CY2022Q1	nmrd	Aggregate Amount AggregateAmount	224600000	usd
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1600000	usd

Files In Submission

Name	View Source	Status
0001079973-23-000949-index-headers.html	Edgar Link	pending
0001079973-23-000949-index.html	Edgar Link	pending
0001079973-23-000949.txt	Edgar Link	pending
0001079973-23-000949-xbrl.zip	Edgar Link	pending
ex21x1.htm	Edgar Link	pending
ex23x1.htm	Edgar Link	pending
ex23x2.htm	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32x1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmra_10k-033123.htm	Edgar Link	pending
nmrd-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
nmrd-20230331_def.xml	Edgar Link	unprocessable
nmrd-20230331_lab.xml	Edgar Link	unprocessable
nmrd-20230331_pre.xml	Edgar Link	unprocessable
nmra_10k-033123_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nmrd-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMRD
Nemaura Medical Inc. Stock $nmrd

2023 Q3 Form 10-K Financial Statement

#000107997323000949 Filed on July 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD Nemaura Medical Inc. Stock $nmrd

2023 Q3 Form 10-K Financial Statement

#000107997323000949 Filed on July 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD
Nemaura Medical Inc. Stock $nmrd